1
|
Lalayanni C, Demosthenous C, Iskas M, Kelaidi C, Papathanasiou M, Syrigou A, Athanasiadou A, Papalexandri A, Batsis I, Vardi A, Polychronopoulou S, Sakellari I. Adolescents and young adults (AYA) with acute myeloid leukemia (AML): real-world long-term results and age-specific outcomes. Leuk Lymphoma 2022; 63:3128-3137. [PMID: 36002396 DOI: 10.1080/10428194.2022.2113527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Opposing acute lymphoblastic leukemia, sparse data about AYAs with acute myeloid leukemia (AML) is available. Overall, 125 AYAs (age 10-35 years) treated during the last two decades were evaluated and compared to 385 older patients. CBF leukemia was more frequent in AYAs (21.6% vs. 8%, p < 0.001); however, many presented high-risk features. AYAs showed improved complete remission rate (CR, 80% vs. 65%, p = 0.01), lower cumulative incidence of relapse and TRM and longer survival (5 year-OS 53% vs. 24%, p < 0.0001), observed mainly in intermediate-risk karyotype. Adolescents displayed even better outcomes (5 year-OS 69%). AlloHCT in CR1 was beneficial for nonadolescent AYAs (5 year-OS 66.7% vs. 44.4% without HCT, p = 0.04). Among 50 APL patients, 19 AYAs experienced better outcomes than older, mainly attributed to reduced treatment-related mortality (TRM, 5% vs. 19%, p = 0.1). We observed an important (>10%) survival gain for AYAs during the last decade. However, AYAs have still unmet needs to obtain optimal cure rates.
Collapse
Affiliation(s)
- Chrysavgi Lalayanni
- Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | | | - Michail Iskas
- Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | - Charikleia Kelaidi
- Department of Pediatric Hematology and Oncology Aghia, Sophia Children's Hospital, Athens, Greece
| | - Maria Papathanasiou
- Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | - Antonia Syrigou
- Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | | | | | - Ioannis Batsis
- Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | - Anna Vardi
- Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | - Sophia Polychronopoulou
- Department of Pediatric Hematology and Oncology Aghia, Sophia Children's Hospital, Athens, Greece
| | - Ioanna Sakellari
- Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| |
Collapse
|
2
|
Voso M, Pandzic T, Falconi G, Denčić‐Fekete M, De Bellis E, Scarfo L, Ljungström V, Iskas M, Del Poeta G, Ranghetti P, Laidou S, Cristiano A, Plevova K, Imbergamo S, Engvall M, Zucchetto A, Salvetti C, Mauro FR, Stavroyianni N, Cavelier L, Ghia P, Stamatopoulos K, Fabiani E, Baliakas P. Clonal haematopoiesis as a risk factor for therapy‐related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo‐(immuno)therapy. Br J Haematol 2022; 198:103-113. [DOI: 10.1111/bjh.18129] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2021] [Accepted: 02/23/2022] [Indexed: 02/06/2023]
Affiliation(s)
- Maria‐Teresa Voso
- Department of Biomedicine and Prevention University of Tor Vergata Rome Italy
| | - Tatjana Pandzic
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory Uppsala University Uppsala Sweden
- Department of Clinical Genetics Uppsala University Hospital Uppsala Sweden
| | - Giulia Falconi
- Department of Biomedicine and Prevention University of Tor Vergata Rome Italy
| | | | - Eleonora De Bellis
- Department of Biomedicine and Prevention University of Tor Vergata Rome Italy
| | - Lydia Scarfo
- Strategic Research Programme in CLL, Division of Experimental Oncology IRCCS Ospedale San Raffaele and Università Vita‐Salute San Raffaele Milan Italy
| | - Viktor Ljungström
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory Uppsala University Uppsala Sweden
- Department of Clinical Genetics Uppsala University Hospital Uppsala Sweden
| | - Michail Iskas
- Hematology Department and HCT Unit, G. Papanicolaou Hospital Thessaloniki Greece
| | - Giovanni Del Poeta
- Department of Biomedicine and Prevention University of Tor Vergata Rome Italy
| | - Pamela Ranghetti
- Strategic Research Programme in CLL, Division of Experimental Oncology IRCCS Ospedale San Raffaele and Università Vita‐Salute San Raffaele Milan Italy
| | - Stamatia Laidou
- Institute of Applied Biosciences Center for Research and Technology Hellas Thessaloniki Greece
| | - Antonio Cristiano
- Department of Biomedicine and Prevention University of Tor Vergata Rome Italy
| | - Karla Plevova
- Institute of Medical Genetics and Genomics Faculty of Medicine Masaryk University Brno Czech Republic
- Department of Internal Medicine – Haematology and Oncology University Hospital Brno Brno Czech Republic
| | - Silvia Imbergamo
- Hematology and Clinical Immunology, Department of Hematology Hospital of Padua Padua Italy
| | - Marie Engvall
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory Uppsala University Uppsala Sweden
- Department of Clinical Genetics Uppsala University Hospital Uppsala Sweden
| | - Antonella Zucchetto
- Clinical and Experimental Onco‐Hematology Unit Centro di Riferimento Oncologico di Aviano (CRO), IRCCS Aviano Italy
| | | | - Francesca R. Mauro
- Department of Translational and Precision Medicine, Hematology 'Sapienza' University Rome Italy
| | - Niki Stavroyianni
- Hematology Department and HCT Unit, G. Papanicolaou Hospital Thessaloniki Greece
| | - Lucia Cavelier
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory Uppsala University Uppsala Sweden
- Department of Clinical Genetics Uppsala University Hospital Uppsala Sweden
| | - Paolo Ghia
- Strategic Research Programme in CLL, Division of Experimental Oncology IRCCS Ospedale San Raffaele and Università Vita‐Salute San Raffaele Milan Italy
| | - Kostas Stamatopoulos
- Institute of Applied Biosciences Center for Research and Technology Hellas Thessaloniki Greece
- Department of Molecular Medicine and Surgery Karolinska Institutet Stockholm Sweden
| | - Emiliano Fabiani
- Department of Biomedicine and Prevention University of Tor Vergata Rome Italy
- UniCamillus‐Saint Camillus International University of Health Sciences Rome Italy
| | - Panagiotis Baliakas
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory Uppsala University Uppsala Sweden
- Department of Clinical Genetics Uppsala University Hospital Uppsala Sweden
| |
Collapse
|
3
|
Vardi A, Vlachonikola E, Papazoglou D, Psomopoulos F, Kotta K, Ioannou N, Galigalidou C, Gemenetzi K, Pasentsis K, Kotouza M, Koravou E, Scarfó L, Iskas M, Stavroyianni N, Ghia P, Anagnostopoulos A, Kouvatsi A, Ramsay AG, Stamatopoulos K, Chatzidimitriou A. T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities. Clin Cancer Res 2020; 26:4958-4969. [PMID: 32616500 DOI: 10.1158/1078-0432.ccr-19-3827] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2019] [Revised: 04/01/2020] [Accepted: 06/25/2020] [Indexed: 11/16/2022]
Abstract
PURPOSE Using next-generation sequencing (NGS), we recently documented T-cell oligoclonality in treatment-naïve chronic lymphocytic leukemia (CLL), with evidence indicating T-cell selection by restricted antigens. EXPERIMENTAL DESIGN Here, we sought to comprehensively assess T-cell repertoire changes during treatment in relation to (i) treatment type [fludarabine-cyclophosphamide-rituximab (FCR) versus ibrutinib (IB) versus rituximab-idelalisib (R-ID)], and (ii) clinical response, by combining NGS immunoprofiling, flow cytometry, and functional bioassays. RESULTS T-cell clonality significantly increased at (i) 3 months in the FCR and R-ID treatment groups, and (ii) over deepening clinical response in the R-ID group, with a similar trend detected in the IB group. Notably, in constrast to FCR that induced T-cell repertoire reconstitution, B-cell receptor signaling inhibitors (BcRi) preserved pretreatment clones. Extensive comparisons both within CLL as well as against T-cell receptor sequence databases showed little similarity with other entities, but instead revealed major clonotypes shared exclusively by patients with CLL, alluding to selection by conserved CLL-associated antigens. We then evaluated the functional effect of treatments on T cells and found that (i) R-ID upregulated the expression of activation markers in effector memory T cells, and (ii) both BcRi improved antitumor T-cell immune synapse formation, in marked contrast to FCR. CONCLUSIONS Taken together, our NGS immunoprofiling data suggest that BcRi retain T-cell clones that may have developed against CLL-associated antigens. Phenotypic and immune synapse bioassays support a concurrent restoration of functionality, mostly evident for R-ID, arguably contributing to clinical response.
Collapse
Affiliation(s)
- Anna Vardi
- Institute of Applied Biosciences, CERTH, Thessaloniki, Greece.,Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.,Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
| | - Elisavet Vlachonikola
- Institute of Applied Biosciences, CERTH, Thessaloniki, Greece.,Faculty of Sciences, Department of Genetics, Development and Molecular Biology, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Despoina Papazoglou
- Lymphoma Immunology Group, School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom
| | - Fotis Psomopoulos
- Institute of Applied Biosciences, CERTH, Thessaloniki, Greece.,Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
| | - Kostantia Kotta
- Institute of Applied Biosciences, CERTH, Thessaloniki, Greece
| | - Nikolaos Ioannou
- Lymphoma Immunology Group, School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom
| | - Chrysi Galigalidou
- Institute of Applied Biosciences, CERTH, Thessaloniki, Greece.,Democritus University of Thrace, Department of Molecular Biology and Genetics, Alexandroupolis, Greece
| | - Katerina Gemenetzi
- Institute of Applied Biosciences, CERTH, Thessaloniki, Greece.,Democritus University of Thrace, Department of Molecular Biology and Genetics, Alexandroupolis, Greece
| | | | - Maria Kotouza
- Institute of Applied Biosciences, CERTH, Thessaloniki, Greece
| | - Evdoxia Koravou
- Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | - Lydia Scarfó
- Division of Experimental Oncology, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy
| | - Michail Iskas
- Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | - Niki Stavroyianni
- Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | - Paolo Ghia
- Division of Experimental Oncology, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy
| | | | - Anastasia Kouvatsi
- Faculty of Sciences, Department of Genetics, Development and Molecular Biology, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Alan G Ramsay
- Lymphoma Immunology Group, School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom
| | - Kostas Stamatopoulos
- Institute of Applied Biosciences, CERTH, Thessaloniki, Greece.,Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
| | - Anastasia Chatzidimitriou
- Institute of Applied Biosciences, CERTH, Thessaloniki, Greece. .,Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
| |
Collapse
|
4
|
Sakellari I, Gavriilaki E, Iskas M, Bousiou Z, Chatziioannidis A, Batsis I, Mallouri D, Constantinous V, Stavroyianni N, Syrigou A, Marvaki A, Pilavaki M, Papaemmanouel S, Anagnostopoulos A. Brentuximab vedotin and anti-PD1 treatment optimize survival in chemo-refractory Hodgkin lymphoma patients: Real-world data. Hematol Oncol 2019; 37:490-492. [PMID: 31339579 DOI: 10.1002/hon.2645] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2019] [Accepted: 06/04/2019] [Indexed: 11/12/2022]
Affiliation(s)
- Ioanna Sakellari
- Hematology Department-BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | - Eleni Gavriilaki
- Hematology Department-BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | - Michail Iskas
- Hematology Department-BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | - Zoi Bousiou
- Hematology Department-BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | | | - I Batsis
- Hematology Department-BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | - Despina Mallouri
- Hematology Department-BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | | | - Niki Stavroyianni
- Hematology Department-BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | - Antonia Syrigou
- Hematology Department-BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | - Anastasia Marvaki
- Hematology Department-BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | - Maria Pilavaki
- Radiology Department, G. Papanicolaou Hospital, Thessaloniki, Greece
| | | | | |
Collapse
|
5
|
Sakellari I, Papalexandri A, Mallouri D, Batsis I, Iskas M, Xochelli A, Marvaki A, Gavriilaki E, Vardi A, Zerva P, Touloumenidou T, Anagnostopoulos A. Donor EBV at the time of hematopoietic cell transplantation: Is it time to adopt molecular assays? J Clin Virol 2018; 102:32-33. [PMID: 29482045 DOI: 10.1016/j.jcv.2018.02.012] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2017] [Revised: 02/16/2018] [Accepted: 02/19/2018] [Indexed: 11/15/2022]
Affiliation(s)
- Ioanna Sakellari
- Hematology Department - BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
| | | | - Despina Mallouri
- Hematology Department - BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | - Ioannis Batsis
- Hematology Department - BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | - Michail Iskas
- Hematology Department - BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | - Aliki Xochelli
- Hematology Department - BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | - Anastasia Marvaki
- Hematology Department - BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | - Eleni Gavriilaki
- Hematology Department - BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | - Anna Vardi
- Hematology Department - BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | - Panagiota Zerva
- Hematology Department - BMT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece
| | | | | |
Collapse
|